Todd Watanabe Franklin's most recent trade in Arcutis Biotherapeutics Inc was a trade of 997 Common Stock done . Disclosure was reported to the exchange on June 10, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, See Remarks | Gift of securities by or to the insider at price $ 0.00 per share. | 10 Jun 2025 | 997 | 914,113 (2%) | 0% | 0 | Common Stock | |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, See Remarks | Gift of securities by or to the insider at price $ 0.00 per share. | 10 Jun 2025 | 997 | 25,410 (0%) | 0% | 0 | Common Stock | |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, See Remarks | Gift of securities by or to the insider at price $ 0.00 per share. | 10 Jun 2025 | 997 | 913,116 (2%) | 0% | 0 | Common Stock | |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, See Remarks | Gift of securities by or to the insider at price $ 0.00 per share. | 10 Jun 2025 | 997 | 25,410 (0%) | 0% | 0 | Common Stock | |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 15.19 per share. | 02 May 2025 | 11,448 | 913,795 (2%) | 0% | 15.2 | 173,917 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 17.56 per share. | 24 Mar 2025 | 2,171 | 925,243 (2%) | 0% | 17.6 | 38,131 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 17.52 per share. | 24 Mar 2025 | 1,500 | 927,414 (2%) | 0% | 17.5 | 26,282 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 17.61 per share. | 17 Mar 2025 | 1,200 | 928,914 (2%) | 0% | 17.6 | 21,137 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 396,000 | 396,000 | - | - | Stock Option (right to buy) | |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 151,000 | 955,129 (2%) | 0% | 0 | Common Stock | |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 13.03 per share. | 28 Feb 2025 | 20,880 | 934,249 (2%) | 0% | 13.0 | 272,089 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 13.28 per share. | 28 Feb 2025 | 4,135 | 930,114 (2%) | 0% | 13.3 | 54,930 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 12.70 per share. | 03 Feb 2025 | 19,301 | 804,129 (2%) | 0% | 12.7 | 245,123 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 15.17 per share. | 20 Dec 2024 | 15,000 | 823,430 (2%) | 0% | 15.2 | 227,567 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 8.68 per share. | 04 Nov 2024 | 13,871 | 832,392 (2%) | 0% | 8.7 | 120,459 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 9.02 per share. | 02 Aug 2024 | 14,487 | 846,263 (2%) | 0% | 9.0 | 130,648 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, See Remarks | Purchase of securities on an exchange or from another person at price $ 1.69 per share. | 31 May 2024 | 4,000 | 836,392 (2%) | 0% | 1.7 | 6,768 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, See Remarks | Purchase of securities on an exchange or from another person at price $ 7.11 per share. | 31 May 2024 | 2,038 | 838,430 (2%) | 0% | 7.1 | 14,482 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 8.74 per share. | 02 May 2024 | 13,783 | 860,750 (2%) | 0% | 8.7 | 120,433 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 11.12 per share. | 04 Mar 2024 | 14,903 | 874,533 (2%) | 0% | 11.1 | 165,739 | Common Stock |
| Arcutis Biotherapeutics Inc | Watanabe Franklin Todd | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 10.60 per share. | 28 Feb 2024 | 2,465 | 889,436 (2%) | 0% | 10.6 | 26,129 | Common Stock |
| Arcutis Biotherapeutics Inc | Franklin Watanabe Todd | Director, See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Feb 2024 | 232,200 | 0 | - | - | Stock Option (right to buy) | |
| Arcutis Biotherapeutics Inc | Watanabe Franklin Todd | Director, See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Feb 2024 | 188,100 | 0 | - | - | Stock Option (right to buy) | |
| Arcutis Biotherapeutics Inc | Watanabe Franklin Todd | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 116,100 | 891,901 (2%) | 0% | - | Common Stock | |
| Arcutis Biotherapeutics Inc | Franklin Watanabe Todd | Director, See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Feb 2024 | 99,200 | 0 | - | - | Stock Option (right to buy) | |
| Arcutis Biotherapeutics Inc | Watanabe Franklin Todd | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 94,050 | 775,801 (2%) | 0% | - | Common Stock | |
| Arcutis Biotherapeutics Inc | Todd Watanabe Franklin | Director, See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Feb 2024 | 65,000 | 0 | - | - | Stock Option (right to buy) | |
| Arcutis Biotherapeutics Inc | Franklin Watanabe Todd | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 33,066 | 681,751 (1%) | 0% | - | Common Stock | |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 21,666 | 648,685 (1%) | 0% | - | Common Stock | |
| Arcutis Biotherapeutics Inc | Todd Watanabe Franklin | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2024 | 410,000 | 410,000 | - | - | Stock Option (right to buy) | |
| Arcutis Biotherapeutics Inc | Watanabe Todd Franklin | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2024 | 125,000 | 627,019 (1%) | 0% | 0 | Common Stock | |
| Arcutis Biotherapeutics Inc | Franklin Todd Watanabe | Director, See Remarks | Gift of securities by or to the insider at price $ 0.00 per share. | 20 Dec 2023 | 6,563 | 24,413 (0%) | 0% | 0 | Common Stock | |
| Arcutis Biotherapeutics Inc | Watanabe Todd Franklin | Director, See Remarks | Gift of securities by or to the insider at price $ 0.00 per share. | 20 Dec 2023 | 6,563 | 508,582 (1%) | 0% | 0 | Common Stock | |
| Arcutis Biotherapeutics Inc | Franklin Todd Watanabe | Director, See Remarks | Gift of securities by or to the insider at price $ 0.00 per share. | 20 Dec 2023 | 6,563 | 24,413 (0%) | 0% | 0 | Common Stock | |
| Arcutis Biotherapeutics Inc | Watanabe Franklin Todd | Director, See Remarks | Gift of securities by or to the insider at price $ 0.00 per share. | 20 Dec 2023 | 6,563 | 502,019 (1%) | 0% | 0 | Common Stock | |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 15.26 per share. | 06 Mar 2023 | 2,435 | 366,657 (0%) | 0% | 15.3 | 37,167 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 232,000 | 232,000 | - | - | Stock Option (right to buy) | |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 87,500 | 456,592 (1%) | 0% | 0 | Common Stock | |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 15.82 per share. | 28 Feb 2023 | 5,403 | 369,161 (0%) | 0% | 15.8 | 85,466 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 16.17 per share. | 28 Feb 2023 | 2,343 | 374,564 (0%) | 0% | 16.2 | 37,878 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 16.52 per share. | 28 Feb 2023 | 69 | 369,092 (0%) | 0% | 16.5 | 1,140 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 17.00 per share. | 13 Feb 2023 | 441 | 377,466 (0%) | 0% | 17 | 7,497 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 17.02 per share. | 13 Feb 2023 | 417 | 377,007 (0%) | 0% | 17.0 | 7,097 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 17.03 per share. | 13 Feb 2023 | 100 | 376,907 (0%) | 0% | 17.0 | 1,703 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 17.00 per share. | 13 Feb 2023 | 42 | 377,424 (0%) | 0% | 17 | 714 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 17.00 per share. | 01 Feb 2023 | 618 | 378,289 (0%) | 0% | 17.0 | 10,509 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 17.00 per share. | 01 Feb 2023 | 382 | 377,907 (0%) | 0% | 17 | 6,494 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 18.00 per share. | 07 Nov 2022 | 1,000 | 379,907 (0%) | 0% | 18.0 | 18,004 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 19.51 per share. | 07 Oct 2022 | 1,000 | 380,907 (1%) | 0% | 19.5 | 19,510 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 07 Sep 2022 | 268,964 | 382,907 (1%) | 0% | 0 | Common Stock | |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 21.51 per share. | 07 Sep 2022 | 1,000 | 381,907 (1%) | 0% | 21.5 | 21,510 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 24.74 per share. | 05 Aug 2022 | 2,500 | 651,871 (1%) | 0% | 24.7 | 61,858 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2022 | 2,500 | 109,348 | - | - | Stock Option (Right to Buy) | |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.68 per share. | 05 Aug 2022 | 2,500 | 654,371 (1%) | 0% | 1.7 | 4,202 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2022 | 7,087 | 111,848 | - | - | Stock Option (Right to Buy) | |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 25.41 per share. | 08 Jul 2022 | 7,087 | 651,871 (1%) | 0% | 25.4 | 180,112 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.68 per share. | 08 Jul 2022 | 7,087 | 658,958 (1%) | 0% | 1.7 | 11,910 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 25.41 per share. | 08 Jul 2022 | 4,913 | 651,871 (1%) | 0% | 25.4 | 124,861 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 08 Jul 2022 | 1,500 | 656,784 (1%) | 0% | 25 | 37,500 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 22.07 per share. | 06 Jul 2022 | 1,000 | 658,284 (1%) | 0% | 22.1 | 22,070 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 21.06 per share. | 06 Jun 2022 | 1,000 | 659,284 (1%) | 0% | 21.1 | 21,064 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 21.76 per share. | 05 May 2022 | 1,000 | 658,667 (1%) | 0% | 21.8 | 21,760 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 21.43 per share. | 05 Apr 2022 | 1,000 | 659,667 (1%) | 0% | 21.4 | 21,430 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 188,100 | 188,100 | - | - | Stock Option (Right to Buy) | |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 70,900 | 663,526 (1%) | 0% | 0 | Common Stock | |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 16.86 per share. | 03 Mar 2022 | 2,489 | 661,037 (1%) | 0% | 16.9 | 41,962 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.68 per share. | 03 Mar 2022 | 700 | 661,667 (1%) | 0% | 1.7 | 1,176 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2022 | 700 | 118,935 | - | - | Stock Option (Right to Buy) | |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 17.11 per share. | 03 Mar 2022 | 700 | 660,967 (1%) | 0% | 17.1 | 11,974 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 16.44 per share. | 03 Mar 2022 | 70 | 660,967 (1%) | 0% | 16.4 | 1,151 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 17.75 per share. | 01 Mar 2022 | 2,153 | 592,626 (1%) | 0% | 17.8 | 38,222 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.68 per share. | 09 Feb 2022 | 1,000 | 595,779 (1%) | 0% | 1.7 | 1,681 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 17.00 per share. | 09 Feb 2022 | 1,000 | 594,779 (1%) | 0% | 17 | 17,000 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2022 | 1,000 | 119,635 | - | - | Stock Option (Right to Buy) | |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2022 | 1,000 | 120,635 | - | - | Stock Option (Right to Buy) | |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.68 per share. | 05 Jan 2022 | 1,000 | 595,779 (1%) | 0% | 1.7 | 1,681 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 21.11 per share. | 05 Jan 2022 | 600 | 594,779 (1%) | 0% | 21.1 | 12,666 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 22.40 per share. | 05 Jan 2022 | 300 | 595,479 (1%) | 0% | 22.4 | 6,720 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 22.06 per share. | 05 Jan 2022 | 100 | 595,379 (1%) | 0% | 22.1 | 2,206 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.68 per share. | 05 Nov 2021 | 1,000 | 595,779 (1%) | 0% | 1.7 | 1,681 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 21.50 per share. | 05 Nov 2021 | 1,000 | 594,779 (1%) | 0% | 21.5 | 21,502 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Nov 2021 | 1,000 | 122,635 | - | - | Stock Option (Right to Buy) | |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.68 per share. | 05 Oct 2021 | 2,500 | 597,279 (1%) | 0% | 1.7 | 4,202 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Oct 2021 | 2,500 | 123,635 | - | - | Stock Option (Right to Buy) | |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 24.92 per share. | 05 Oct 2021 | 2,500 | 594,779 (1%) | 0% | 24.9 | 62,294 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2021 | 1,500 | 126,135 | - | - | Stock Option (Right to Buy) | |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 25.01 per share. | 01 Oct 2021 | 1,500 | 594,779 (1%) | 0% | 25.0 | 37,510 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.68 per share. | 01 Oct 2021 | 1,500 | 596,279 (1%) | 0% | 1.7 | 2,521 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.68 per share. | 07 Sep 2021 | 1,000 | 595,779 (1%) | 0% | 1.7 | 1,681 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 21.14 per share. | 07 Sep 2021 | 1,000 | 594,779 (1%) | 0% | 21.1 | 21,137 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Sep 2021 | 1,000 | 127,635 | - | - | Stock Option (Right to Buy) | |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.68 per share. | 05 Aug 2021 | 1,000 | 595,779 (1%) | 0% | 1.7 | 1,681 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2021 | 1,000 | 128,635 | - | - | Stock Option (Right to Buy) | |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 20.81 per share. | 05 Aug 2021 | 1,000 | 594,779 (1%) | 0% | 20.8 | 20,810 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.68 per share. | 06 Jul 2021 | 1,750 | 596,529 (1%) | 0% | 1.7 | 2,941 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 26.58 per share. | 06 Jul 2021 | 1,750 | 594,779 (1%) | 0% | 26.6 | 46,515 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jul 2021 | 1,750 | 129,635 | - | - | Stock Option (Right to Buy) | |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Other type of transaction at price $ 0.00 per share. | 18 Jun 2021 | 7,377 | 57,358 (0%) | 0% | 0 | Common Stock | |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 26.35 per share. | 07 Jun 2021 | 1,750 | 594,779 (1%) | 0% | 26.4 | 46,113 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.68 per share. | 07 Jun 2021 | 1,750 | 596,529 (1%) | 0% | 1.7 | 2,941 | Common Stock |
| Arcutis Biotherapeutics Inc | Todd Franklin Watanabe | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2021 | 1,750 | 131,385 | - | - | Stock Option (Right to Buy) |